Lexaria Bioscience Corp. (LEXX)

CA — Healthcare Sector
Peers: ANL  PTHS  EDSA  ASBP  PALI  FBLG  DARE  SNSE  LPCN  PULM 

Automate Your Wheel Strategy on LEXX

With Tiblio's Option Bot, you can configure your own wheel strategy including LEXX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LEXX
  • Rev/Share 0.0337
  • Book/Share 0.2823
  • PB 3.2414
  • Debt/Equity 0.021
  • CurrentRatio 3.9021
  • ROIC -2.1576

 

  • MktCap 19275354.0
  • FreeCF/Share -0.5339
  • PFCF -1.9731
  • PE -1.5799
  • Debt/Assets 0.0173
  • DivYield 0
  • ROE -1.4935

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
LEXX
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral

Additions broaden DehydraTECH patent suite for Epilepsy KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy. "We are thrilled to have received broadened claims related to our proprietary DehydraTECH™ technology for the treatment of epilepsy," said Rich Christopher, CEO of Lexaria.

Read More
image for news Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
LEXX
Published: February 11, 2025 by: TheNewswire
Sentiment: Neutral

Additions broaden DehydraTECH patent suite for Epilepsy Kelowna, British Columbia – TheNewswire - February 11, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy.

Read More
image for news Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

About Lexaria Bioscience Corp. (LEXX)

  • IPO Date 2021-01-12
  • Website https://www.lexariabioscience.com
  • Industry Biotechnology
  • CEO Richard C. Christopher
  • Employees 7
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.